capecitabine + tislelizumab

Capecitabine + tislelizumab is an investigational combination therapy consisting of capecitabine, an oral prodrug of 5-fluorouracil (a cytotoxic antimetabolite), and tislelizumab, a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1). Capecitabine inhibits DNA synthesis in rapidly dividing cells by interfering with thymidylate synthase after conversion to 5-FU. Tislelizumab blocks the PD-1 receptor on T cells, preventing tumor-mediated immune suppression and enhancing anti-tumor immune responses. This combination is being studied primarily for use in solid tumors such as biliary tract cancer and nasopharyngeal carcinoma, aiming to leverage both direct cytotoxic effects and immune checkpoint inhibition for improved efficacy[1][2][3].

Brand names

TevimbraXeloda

Other names

PD-1 antibody + capecitabineadjuvant tislelizumab plus metronomic capecitabine